ROPIN 0.2% INJECTION 50ML

In stock
SKU
ROP0039
₹254.00 Inclusive of all taxes
Manufacturer : NEP-NEON LABORATORIES LTD
Composition : ROPIVACAINE-0.2%
Dose Form : INJECTION
Description : ROPIN 0.2% 50ML INJ
Route Of Administration : PARENTERAL
Pack : 1

Drug Ingredient Information

ROPIVACAINE-0.2%

ROPIVACAINE

Information for patients
Drug Information Ropivacaine hcl is indicated for the production of local or regional anesthesia for surgery and for acute pain management. Surgical Anesthesia: epidural block for surgery including cesarean section; major nerve block; local infiltration Acute Pain Management: epidural continuous infusion or intermittent bolus, eg, postoperative orlabor; local infiltration
Drug Alert
Alert no data available
Before Consuming the Medicine
Avoid Drug You should not receive ropivacaine if you have ever had an allergic reaction to any type of numbing medicine. Before receiving ropivacaine, tell your doctor if you are allergic to any drugs, or if you have liver disease, heart disease, or kidney disease. Tell your caregivers at once if you have a serious side effect such as: confusion, feeling like you might pass out, problems with speech or vision, ringing in your ears, numbness or tingling around your mouth, seizure, weak or shallow breathing, fast or slow heart rate, weak pulse, gasping, or feeling unusually hot. This medication can cause numbness over a large portion of your body. Take care to avoid injury before the feeling has returned completely. Spinal numbing medications can have long-lasting or permanent effects on certain body processes such as sexual function, bowel or bladder control, and movement or feeling in your legs or feet. Talk with your doctor about your specific risk of nerve damage from ropivacaine.
Drug Special Care You should not receive ropivacaine if you have ever had an allergic reaction to any type of numbing medicine. Before receiving ropivacaine, tell your doctor if you are allergic to any drugs, or if you have: liver disease; heart disease; or kidney disease. If you have any of these conditions, you may need a dose adjustment or special tests to safely receive ropivacaine. FDA pregnancy category B. This medication is not expected to be harmful to an unborn baby. It is not known whether ropivacaine can pass into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.
Drug Drug Interactions Many drugs can interact with ropivacaine. Below is just a partial list. Tell your doctor if you are using: birth control pills or other hormones; cimetidine (Tagamet); cyclobenzaprine (Flexeril); interferon (Actimmune, Roferon, Intron, Rebetron, and others); ondansetron (Zofran); propranolol (Inderal); theophylline (Elixophyllin, Respbid, Slo-Bid, Theobid, Theo-Dur); verapamil (Calan, Covera, Isoptin, Verelan); warfarin (Coumadin); a heart rhythm medication such as amiodarone (Cordarone, Pacerone), bretylium (Bretylan, Tosylate), dofetilide (Tikosyn), ibutilide (Corvert), mexiletine (Mexitil), or sotalol (Betapace); antidepressants such as amitriptyline (Elavil, Etrafon), clomipramine (Anafranil), fluvoxamine (Luvox), imipramine (Janimine, Tofranil); or medicines to treat psychiatric disorders, such as clozapine (Clozaril, Fazaclo), haloperidol (Haldol), olanzapine (Zyprexa, Zydis). This list is not complete and there may be other drugs that can interact with ropivacaine. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
Drug Pregnancy Interaction Ropivacaine has been assigned to pregnancy category B by the FDA. Animal studies utilizing doses up to 5 times the maximum recommended human dose have not revealed evidence of teratogenicity. Higher dosages (23 mg/kg) have resulted in increased pup loss during the first 3 days postpartum, thought to be secondary to decreased maternal care due to maternal toxicity. There are no controlled data in human pregnancy. Ropivacaine should be used in pregnancy only when need has been clearly established. Ropivacaine has been shown to rapidly cross the placenta. Adverse reactions in the mother and/or neonate are dependent upon the route of administration, procedure and amount of drug used. Toxic reactions may include alterations in the central nervous system, peripheral vascular tone and cardiac function. Maternal hypotension during obstetrical procedures has occurred during regional anesthesia with ropivacaine. Elevating the patient's legs and positioning on the left side will help to prevent this effect. The fetal heart rate should be continuously monitored. Compared to bupivacaine 0.25%, ropivacaine 0.25% given by epidural infusion for pain relief during labor and delivery produced no significant differences in neonatal Apgar scores, umbilical acid-base status and neurological and adaptive capacity score at 2 and 24 hours after delivery. The ropivacaine group had a higher incidence of spontaneous vaginal delivery. Maternal pain relief was comparable and effective. In another comparative study, similar results were reported and, in addition, a lower percentage of instrumental deliveries occurred with ropivacaine.
Drug Breast feeding Interaction There are limited data on the excretion of ropivacaine into human milk. However, animal studies suggest that the amount of ropivacaine that a nursing infant would be exposed to is considerably less than by exposure in utero at term.
Drug Machinery Interaction no data available
Drug More Information This medication can cause numbness over a large portion of your body. Take care to avoid injury before the feeling has returned completely.
How to take the Medicine
Consumption Info no data available
Drug quanitty Ropivacaine is given as an injection through a needle placed into an area of your middle or lower back near your spine. You will receive this injection in a clinic or hospital setting. Your breathing, blood pressure, oxygen levels, and other vital signs will be watched closely while you are receiving ropivacaine. Spinal numbing medications can have long-lasting or permanent effects on certain body processes such as sexual function, bowel or bladder control, and movement or feeling in your legs or feet. Talk with your doctor about your specific risk of nerve damage from ropivacaine.
Drug Dose The rapid injection of a large volume of local anesthetic solution should be avoided and fractional (incremental) doses should always be used. The smallest dose and concentration required to produce the desired result should be administered. There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Naropin is not approved for this use (see WARNINGS). The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. Patients in poor general condition due to aging or other compromising factors such as partial or complete heart conduction block, advanced liver disease or severe renal dysfunction require special attention although regional anesthesia is frequently indicated in these patients. To reduce the risk of potentially serious adverse reactions, attempts should be made to optimize the patient's condition before major blocks are performed, and the dosage should be adjusted accordingly. Use an adequate test dose (3 to 5 mL of a short acting local anesthetic solution containing epinephrine) prior to induction of complete block. This test dose should be repeated if the patient is moved in such a fashion as to have displaced the epidural catheter. Allow adequate time for onset of anesthesia following administration of each test dose. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Solutions that are discolored or that contain particulate matter should not be administered.When prolonged blocks are used, either through continuous infusion or through repeated bolus administration, the risks of reaching a toxic plasma concentration or inducing local neural injury must be considered. Experience to date indicates that a cumulative dose of up to 770 mg Naropin (ropivacaine hcl) administered over 24 hours is well tolerated in adults when used for postoperative pain management: ie, 2016 mg. Caution should be exercised when administering Naropin (ropivacaine hcl) for prolonged periods of time, eg, > 70 hours in debilitated patients. For treatment of postoperative pain, the following technique can be recommended: If regional anesthesia was not used intraoperatively, then an initial epidural block with 5 to 7 mL Naropin (ropivacaine hcl) is induced via an epidural catheter. Analgesia is maintained with an infusion of Naropin (ropivacaine hcl) , 2 mg/mL (0.2%). Clinical studies have demonstrated that infusion rates of 6 to 14 mL (12 to 28 mg) per hour provide adequate analgesia with nonprogressive motor block. With this technique a significant reduction in the need for opioids was demonstrated. Clinical experience supports the use of Naropin (ropivacaine hcl) epidural infusions for up to 72 hours.The solubility of ropivacaine is limited at pH above 6. Thus, care must be taken as precipitation may occur if Naropin (ropivacaine hcl) is mixed with alkaline solutions. Disinfecting agents containing heavy metals, which cause release of respective ions (mercury, zinc, copper, etc.) should not be used for skin or mucous membrane disinfection since they have been related to incidents of swelling and edema. When chemical disinfection of the container surface is desired, either isopropyl alcohol (91%) or ethyl alcohol (70%) is recommended. It is recommended that chemical disinfection be accomplished by wiping the ampule or vial stopper thoroughly with cotton or gauze that has been moistened with the recommended alcohol just prior to use. When a container is required to have a sterile outside, a Sterile-Pak should be chosen. Glass containers may, as an alternative, be autoclaved once. Stability has been demonstrated using a targeted F0 of 7 minutes at 121°C. Solutions should be stored at 20º to 25°C (68º to 77°F) [see USP Controlled Room Temperature]. These products are intended for single use and are free from preservatives. Any solution remaining from an opened container should be discarded promptly. In addition, continuous infusion bottles should not be left in place for more than 24 hours.
Excess Drug Consumption Tell your caregivers right away if you think you have received too much of this medicine. Overdose symptoms may include extreme drowsiness, ringing in your ears, blurred vision, fainting, seizure (convulsions), weak or shallow breathing, or breathing that stops.
Forgot Drug Consumption Since ropivacaine is given as needed before a surgery or other medical procedure, you are not likely to be on a dosing schedule.
Stop Drug Consumption Do not stop the drug untill your doctor says you to do so.
Possible Side Effects
General Information no data available
Common Drug Side Effects feeling anxious, restless, confused, or like you might pass out; problems with speech or vision; ringing in the ears, metallic taste, vision problems, numbness or tingling around your mouth, or tremors; seizure (convulsions); weak or shallow breathing; slow heart rate, weak pulse; or fast heart rate, gasping, feeling unusually hot.
Rare Drug Side Effects nausea, vomiting; headache, back pain; fever; itching; numbness or tingly feeling; or problems with urination or sexual function.
Very Rare Drug Side Effects no data available
Drug Side Effects Symptoms no data available
How to Store the Medicine
How to Store the Medicine Store in a cool and dark place

Substitute Drugs

Write Your Own Review
You're reviewing:ROPIN 0.2% INJECTION 50ML
Your Rating